Switching between covered GLP-1s
Published by GLP-1 Coverage Guide · Updated · No clinician review is credited for this page.
Short answer: You can switch among Wegovy, Zepbound (KwikPen), and Foundayo within the Bridge — all three cost the same $50 — with a new prior authorization when changing to a different covered drug. Your prescriber determines the dose, timing and follow-up; this guide does not prescribe a restart schedule.
Sources for the coverage rules are listed below. An update date marks a revision; it does not imply a sitewide medical review.
When switching makes sense — and when patience does
Good reasons to switch: persistent intolerable side effects after a fair trial, a plateau your prescriber thinks the other molecule might break (the tirzepatide efficacy edge in trial averages is real), or sustained supply problems with your current product. Weaker reasons: slow first-month results (early doses are adaptation doses — effects build through the middle of titration) or single missed-stock incidents a pharmacy transfer would solve.
Mechanics: your prescriber submits the change, the prescriber determines the new drug’s dosing instructions, and each monthly fill remains $50. Remember the form rule changes with the drug — switching to Zepbound means KwikPen, explicitly, on the prescription.
Take the Medicare eligibility check →
Common questions
Will I lose ground during a switch?
Some patients hold steady through the transition; some regain slightly during the new titration's early weeks. Your prescriber can sequence the change to minimize the gap.
Does a switch cost anything extra?
No — it's the same $50 per fill on the new drug. The cost is time spent back at sub-maintenance doses.
How many switches does the program allow?
No published cap — it's governed by clinical reasonableness and your prescriber's willingness to document the rationale.
Related
Sources: CMS Medicare GLP-1 Bridge